Financial Performance Expectations - The company expects net profit attributable to shareholders to be between 38,000 and 48,000 thousand yuan, representing a year-on-year growth of 60.03% to 102.14% compared to 23,746 thousand yuan in the previous year[3]. - The net profit after deducting non-recurring gains and losses is projected to be between 28,374 and 38,374 thousand yuan, indicating a year-on-year increase of 98.32% to 168.22% from 14,307 thousand yuan last year[3]. - Basic earnings per share are expected to be between 0.75 and 0.95 yuan per share, compared to 0.47 yuan per share in the previous year[3]. Revenue and Operational Highlights - The main reason for the performance change is the increase in revenue from blood products and the low base effect from goodwill impairment and other asset impairment in the previous year[5]. - The company achieved a plasma collection volume of 522.04 tons from 16 operating plasma stations, marking an 11.71% year-on-year growth[5]. Non-Recurring Gains and Losses - The estimated impact of non-recurring gains and losses on net profit is approximately 9,626 thousand yuan[5]. Audit and Reporting - The financial data in this earnings forecast has not been audited by a registered accounting firm[4]. - The specific data will be detailed in the company's 2024 annual report[7]. Investment Advisory - Investors are advised to make cautious decisions and be aware of investment risks[7]. - The earnings forecast period is from January 1, 2024, to December 31, 2024[3].

特别提示： 1、本次申请解除限售股份为华润博雅生物制药集团股份有限公司（以下简 称公司）向特定对象华润医药控股有限公司发行的 78,308,575 股份，本次解除限 售股份数量为 78,308,575 股，占公司总股本的 15.5298%；本次解除限售后实际 可上市流通的股份数量为 78,308,575 股，占公司总股本的 15.5298%。 2、本次限售股份可上市流通日：2024 年 11 月 25 日（星期一）。 一、公司发行股份概况 证券代码：300294 证券简称：博雅生物 公告编号：2024-073 华润博雅生物制药集团股份有限公司 关于向特定对象发行股票解除限售上市流通的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 2021 年 10 月 26 日，公司收到中国证券监督委员会（以下简称中国证监会） 出具的《关于核准博雅生物制药集团股份有限公司向特定对象发行股票注册的批 复》（证监许可[2021]3340 号），同意公司向特定对象发行股票的注册申请。公 司向特定对象华润医药控股有限公司发行股票 78,308,575 股，本次发行完成后， 公司 ...

证券代码：300294 证券简称：博雅生物 公告编号：2024-070 华润博雅生物制药集团股份有限公司 关于使用部分闲置自有资金进行现金管理的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 为合理利用闲置自有资金，提高自有资金使用效率和收益，在保障华润博雅 生物制药集团股份有限公司（以下简称公司）正常运营的情况下，公司于2024 年10月23日召开第八届董事会第六次会议、第八届监事会第七次会议，审议通过 了《关于使用部分闲置自有资金进行现金管理的议案》，公司拟使用不超过人民 币250,000.00万元的闲置自有资金进行现金管理，以实现资金收益，上述额度可 滚动使用，管理期限自董事会审议通过之日起12个月内有效。公司监事会对该事 项发表了意见。现将有关情况公告如下： （二）投资品种 公司进行现金管理，投资的品种范围为向银行、银行理财子公司等金融机构 购买的大额可转让存单或中低风险（PR2）及以下等级的银行理财产品等，同时 不影响自有资金投资计划正常进行和公司正常经营。上述投资产品不得质押，使 用闲置自有资金购买产品专用结算账户不得存放非自有资金或用作其他用途。 ...

中信证券股份有限公司 关于华润博雅生物制药集团股份有限公司 使用部分闲置募集资金进行现金管理的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）作为华润博雅 生物制药集团股份有限公司（以下简称"博雅生物"或"公司"）的保荐机构，《证 券发行上市保荐业务管理办法》《深圳证券交易所创业板股票上市规则》《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等相关 法律、法规和规范性文件的规定，对博雅生物使用部分闲置募集资金进行现金管 理事项进行了核查，现将核查情况及核查意见发表如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准博雅生物制药集团股份有限公司非公 开发行股票的批复》（证监许可[2018]117 号）核准，公司向 4 名特定投资者非 公开发行股票 32,247,662 股，发行价格为 31.01 元/股，募集资金总额为 999,999,998.62 元，扣除各项发行费用 10,744,000.00 元，募集资金净额为 989,255,998.62 元。上述募集资金已经江苏公证天业会计师事务所（特殊普通合 伙）审验，并于 2018 年 4 月 9 日出具 ...

Financial Performance - Q3 2024 revenue was CNY 349,372,113.05, a decrease of 46.21% year-over-year, while total revenue for the first nine months was CNY 1,245,107,779.60, down 43.16% compared to the same period last year[2]. - Net profit attributable to shareholders for Q3 2024 was CNY 96,733,318.26, a decline of 29.98% year-over-year, with a nine-month total of CNY 412,703,629.27, down 11.07%[2]. - Operating revenue for the first nine months of 2024 was approximately ¥1.25 billion, a decrease of 43.16% compared to ¥2.19 billion in the same period of 2023[7]. - Total operating revenue for Q3 2024 was CNY 1,245,107,779.60, a decrease of 43.2% compared to CNY 2,190,398,869.51 in the same period last year[20]. - The net profit for Q3 2024 was CNY 412.43 million, a decrease of 13.00% compared to CNY 474.09 million in Q3 2023[21]. - The total profit for Q3 2024 was CNY 480.43 million, compared to CNY 575.20 million in Q3 2023, a decline of 16.49%[21]. Revenue and Costs - Total operating costs for Q3 2024 were CNY 853,438,255.57, down 51.2% from CNY 1,749,069,896.51 year-over-year[20]. - Operating costs for the same period were approximately ¥415 million, down 62.07% from ¥1.09 billion year-on-year[7]. - Cash received from sales of goods and services was approximately ¥1.19 billion, a decline of 47.40% compared to ¥2.25 billion in 2023[7]. - Cash paid for purchasing goods and services was approximately ¥334 million, down 63.82% from ¥923 million year-on-year[7]. - Sales expenses decreased by 39.71% to approximately ¥274 million from ¥454 million in the previous year[7]. - The company reported a significant reduction in sales expenses, which decreased to CNY 273,785,234.14 from CNY 454,124,674.39, a decline of 39.6%[20]. Assets and Equity - Total assets as of September 30, 2024, were CNY 8,157,947,458.71, reflecting a 4.20% increase from the end of the previous year[2]. - Shareholders' equity increased to CNY 7,581,179,585.65, up 3.57% from the end of the previous year[2]. - The company's total equity attributable to shareholders increased to CNY 7,581,179,585.65, compared to CNY 7,319,750,577.78, marking a growth of 3.6%[19]. - The company’s total current assets increased to RMB 6.59 billion from RMB 6.43 billion at the beginning of the period, reflecting a growth of approximately 2.5%[17]. - The company’s inventory rose to RMB 627.58 million, up from RMB 556.94 million, indicating an increase of about 12.7%[17]. - The company’s cash and cash equivalents at the end of the period were RMB 1.99 billion, compared to RMB 1.96 billion at the beginning, showing a slight increase of 1.4%[17]. Cash Flow - Cash flow from operating activities for the first nine months was CNY 262,408,653.79, a significant decrease of 50.08% compared to the same period last year[2]. - Cash flow from operating activities decreased to CNY 262.41 million in Q3 2024, compared to CNY 525.71 million in Q3 2023, a drop of 50.16%[23]. - The company reported a net cash inflow of approximately ¥109 million from the disposal of subsidiaries, a significant increase of 200.18% compared to ¥36 million in the previous year[7]. - The company recorded a net cash outflow from investment activities of CNY 53.56 million in Q3 2024, an improvement from a net outflow of CNY 519.77 million in Q3 2023[23]. - Cash flow from financing activities showed a net outflow of CNY 170.21 million in Q3 2024, compared to a net outflow of CNY 193.63 million in the same period last year, indicating a reduction of 12.56%[24]. Investments and Acquisitions - The company plans to increase investment in smart factory projects, with cash payments for fixed assets rising by 59.99% to approximately ¥119 million[7]. - The company has made a cash payment of ¥182 million related to the acquisition of Green Cross, indicating ongoing market expansion strategies[7]. - The company completed the acquisition of 100% equity in Green Cross Hong Kong Holdings Limited for RMB 1.82 billion, indirectly acquiring Green Cross (China) Biological Products Co., Ltd.[11]. Plasma Collection and Production - The blood products business generated revenue of CNY 1,089,481,025.84 for the first nine months, an increase of 0.39% year-over-year, driven by higher sales of prothrombin complex and factor VIII[3]. - The company collected 387.44 tons of raw plasma in the first nine months, representing a 12.39% increase compared to the previous year, due to improved local donation environments and service quality[3]. - The company’s subsidiary, Taihe Plasma Station, and Leping Plasma Station received the Single Plasma Collection License, enhancing the raw plasma supply capacity.[12]. - The company is actively advancing the construction of its intelligent blood product factory, with major structural work completed, marking a new phase in the project.[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,602, indicating a stable shareholder base[8]. - The company’s cash dividend distribution for the first half of 2024 is set at RMB 1.60 per 10 shares, totaling RMB 80.68 million, which accounts for 25.53% of the net profit attributable to shareholders for the same period.[14]. Research and Development - Research and development expenses for Q3 2024 amounted to CNY 47,378,915.31, slightly down from CNY 48,042,073.01 in the previous year[20].

华润博雅生物制药集团股份有限公司（以下简称公司）董事会于2024年10 月21日收到公司非独立董事孙金妮女士递交的书面《辞任报告》，孙金妮女士因 工作调动原因申请辞去公司第八届董事会董事及战略与ESG委员会委员职务，辞 任后将不再担任公司任何职务。孙金妮女士的辞任不会影响公司的正常生产运 营。截至本公告披露日，孙金妮女士未持有公司股份，不存在应履行而未履行的 承诺事项。 证券代码：300294 证券简称：博雅生物 公告编号：2024-065 华润博雅生物制药集团股份有限公司 关于公司董事辞任的公告 本公司及董事会全体成员保证公告内容真实，准确和完整，没有虚假记载， 误导性陈述或重大遗漏。 特此公告。 华润博雅生物制药集团股份有限公司董事会 2024 年 10 月 21 日 孙金妮女士的辞任未导致公司董事会人数低于法定最低人数，不会影响公司 董事会的正常运作，根据《中华人民共和国公司法》《深圳证券交易所上市公司 自律监管指引第2号——创业板上市公司规范运作》及《公司章程》等有关规定， 孙金妮女士辞任报告自送达公司董事会之日起生效。公司董事会将按照有关规定 尽快完成董事补选工作。 孙金妮女士作为公司非独立董事的原 ...

证券代码：300294 证券简称：博雅生物 公告编号：2024-053 华润博雅生物制药集团股份有限公司 第八届董事会第五次会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 华润博雅生物制药集团股份有限公司（以下简称公司）第八届董事会第五次 会议于 2024 年 8 月 12 日以邮件及通讯方式通知，并于 2024 年 8 月 22 日在公司 会议室以现场加通讯表决的方式召开。会议应参加表决董事 9 人，实参加表决董 事 9 人。会议由董事长邱凯先生主持，公司全体监事出席会议，全体高级管理人 员列席会议。本次会议符合《中华人民共和国公司法》（以下简称《公司法》）、 《中华人民共和国证券法》（以下简称《证券法》）、《深圳证券交易所创业板 股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》及《公司章程》等相关规定。经充分讨论，审议通过了以下议案。 二、董事会会议审议情况 1、审议通过《关于公司<2024 年半年度报告全文及摘要>的议案》 经审议，董事会认为：公司编制的《2024 年半年度报告全文 ...

Financial Performance - The company's operating revenue for the reporting period was ¥895,735,666.55, a decrease of 41.87% compared to ¥1,540,872,254.12 in the same period last year[13]. - Net profit attributable to shareholders was ¥315,970,311.01, down 3.05% from ¥325,918,480.96 year-on-year[13]. - The net cash flow from operating activities was ¥211,660,633.61, reflecting a decline of 46.17% compared to ¥393,183,884.50 in the previous year[13]. - The total assets at the end of the reporting period amounted to ¥8,023,345,740.98, representing an increase of 2.48% from ¥7,828,900,301.89 at the end of the previous year[13]. - The company achieved total operating revenue of ¥895,735,666.55, a decrease of 41.87% compared to the same period last year[34]. - The blood products business generated operating income of ¥790,132,233.58, an increase of 3.64% year-on-year, primarily due to increased sales of PCC and factor VIII[34]. - The biochemical drug business reported operating income of ¥101,578,802.9, a decrease of 44.98% year-on-year, impacted by procurement policies[34]. - The company reported a net profit attributable to shareholders of ¥315,970,311.01, a decrease of 3.05% year-on-year, mainly due to the exclusion of certain subsidiaries from the consolidated financial statements[34]. - The company reported a significant increase of 698.86% in cash flow from investment activities, totaling approximately ¥1.23 billion, due to increased financial management cash flow and equity transfer proceeds[43]. - The company’s total comprehensive income for the first half of 2024 was ¥319,150,548.57, down from ¥552,349,969.28 in the same period of 2023, indicating a decline of about 42.2%[128]. Dividend Distribution - The company plans to distribute a cash dividend of 1.60 RMB per 10 shares, based on a total of 504,248,738 shares[2]. - The cash dividend distribution represents 100% of the total distributable profit, amounting to approximately 2.70 billion RMB[73]. Acquisitions and Subsidiaries - The company has fully acquired 100% equity of Green Cross (Hong Kong) in July 2024[6]. - The company completed the acquisition of 100% equity in Green Cross Hong Kong Holdings Limited for RMB 1.82 billion, indirectly acquiring Green Cross (China) Biological Products Co., Ltd.[110]. - The company has a total of 9 wholly-owned subsidiaries involved in blood plasma collection[6]. - The company’s subsidiary, New Biopharmaceuticals, reported a net profit of RMB 8,003,375.89, while another subsidiary, Boya Xinhao, reported a net loss of RMB 11,315,816.01[65]. Production and Operations - The company collected 246.89 tons of raw plasma during the reporting period, marking a year-on-year increase of 14.63%[18]. - The company has 16 single plasma collection stations, with two new stations obtaining licenses in July 2024[18]. - The company achieved a total of 189,814 bottles of human albumin (5g/bottle) in the first half of 2024, representing an 18.7% increase compared to 159,907 bottles in the same period of 2023[22]. - The production of human immunoglobulin (5g/bottle) increased by 6.6%, with 107,614 bottles produced in the first half of 2024 compared to 100,944 bottles in the same period of 2023[22]. - The production of human coagulation factor VIII decreased by 74.8%, with only 11,301 bottles produced in the first half of 2024 compared to 44,806 bottles in the same period of 2023[23]. - The company has established a complete standardized business management system for plasma collection, covering all aspects from blood source registration to plasma storage and transportation[27]. - The company is focused on becoming a world-class blood products enterprise while gradually stabilizing and divesting non-blood product businesses[19]. Research and Development - The company aims to enhance its research and development efforts to diversify its product line and improve plasma utilization rates[18]. - The company is actively pursuing R&D in blood products, with key projects such as IVIG and vWF in clinical trial stages, and plans to apply for drug registration certificates[30]. - The company has established multiple R&D platforms and partnerships with universities and research institutions to strengthen its innovation capabilities[30]. - The company focuses on biochemical drug research and development, with a complete product structure and a leading market position in core products such as bone peptide series and oxytocin series[23]. Financial Position - Cash and cash equivalents increased to ¥3,252,295,313.33, representing 40.54% of total assets, up from 25.05% last year, a change of 15.49%[46]. - The company reported a total investment of ¥2,881,673,432.95 for the reporting period, a decrease of 15.07% compared to ¥3,393,069,430.69 in the same period last year, mainly due to reduced purchases of financial products[50]. - The company’s long-term borrowings were reclassified to current liabilities, totaling ¥22,961,005.13, reflecting a significant increase from ¥907,054.30 last year[47]. - The company’s inventory stood at ¥577,321,177.61, accounting for 7.20% of total assets, showing no significant change from the previous year[46]. - The company’s total liabilities increased to ¥3,200,000,000, reflecting a rise of 5% compared to the previous period[120]. Environmental Compliance - The company has received environmental impact report approvals for all existing projects, ensuring compliance with environmental regulations[76]. - Huaren Boya Bio achieved a total pollutant discharge of 3.0025 tons for COD, well below the approved limit of 13.36 tons[77]. - The company has implemented pollution prevention measures as outlined in their environmental impact reports, ensuring minimal environmental impact[76]. - All companies under Huaren Boya Bio have been classified as non-key pollutant discharge units by environmental authorities, reflecting their commitment to environmental responsibility[75]. Risk Management - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[2]. - The company faces risks related to the supply of raw materials, specifically human plasma, which is tightly regulated and affects production capacity[65]. - The company will conduct comprehensive market research before launching new products to mitigate risks associated with product development and ensure alignment with market demand[66]. - The company has established a robust quality management system to control product quality risks, which is critical for maintaining brand reputation and market position[66]. Shareholder Information - The total number of shares after the recent changes is 504,248,738, with 15.53% being restricted shares and 84.47% being unrestricted shares[112]. - The largest shareholder, China Resources Pharmaceutical Group, holds 29.28% of the shares, totaling 147,640,553[113]. - The report indicates that there were no changes in the number of shares held by the top shareholders during the reporting period[113]. Corporate Governance - The half-year financial report was not audited, and there were no significant guarantees or major contracts affecting the company's profit during the reporting period[95][109]. - The company has not implemented any employee stock ownership plans or other incentive measures during the reporting period[74]. - There were no significant lawsuits or arbitration matters during the reporting period[96].

华润博雅生物制药集团股份有限公司 关于对江西博雅欣和制药有限公司增资的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 证券代码：300294 证券简称：博雅生物 公告编号：2024-058 一、本次增资概述 根据华润博雅生物制药集团股份有限公司（以下简称公司）战略发展规划， 为压降高负债子企业工作，改善江西博雅欣和制药有限公司（以下简称博雅欣和） 财务状况，公司于 2024 年 8 月 22 日召开第八届董事会第五次会议，审议通过《关 于对江西博雅欣和制药有限公司增资的议案》，同意公司拟使用自有资金人民币 48,687.80 万元对博雅欣和进行增资。 根据《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自 律监管指引第 2 号——创业板上市公司规范运作》等相关规定，本次交易金额人 民币 48,687.80 万元，占公司最近一期经审计净资产的 6.65%，该事项无需提交 公司股东大会审议。 本次交易不属于《上市公司重大资产重组管理办法》规定的重大资产重组， 不构成重组上市，本次交易亦不构成关联交易。截至本公告日，该事项已获得公 司主管部门的批复 ...

2024 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：300294 证券简称：博雅生物 公告编号：2024-056 根据《中华人民共和国公司法》（以下简称《公司法》）、《中华人民共和 国证券法》（以下简称《证券法》）、《深圳证券交易所上市公司自律监管指引 第2号——创业板上市公司规范运作》（以下简称《上市公司规范运作》）、《深 圳证券交易所创业板股票上市规则》（以下简称《股票上市规则》）、《上市公 司监管指引第2号——上市公司募集资金管理和使用的监管要求》《深圳证券交 易所创业板上市公司自律监管指南第2号——公告格式》相关格式指引的规定及 要求，华润博雅生物制药集团股份有限公司（以下简称公司或华润博雅生物）编 制了截至2024年06月30日的"2024年半年度募集资金存放与使用情况的专项报 告"。具体情况如下： 华润博雅生物制药集团股份有限公司 一、2018 年非公开发行募集资金基本情况 （一）募集资金金额和实际到账时间 根据公司2017年第二次临时股东大会会议决议及中国证券监督管理委员会 《关于核准博雅生物制 ...